

2023 CHESAPEAKE AIHA/ASSP EDUCATIONAL SEMINAR

NALOXONE IN THE WORKPLACE

Clifford S. Mitchell, MS, MD, MPH

Director, Environmental Health Bureau

Maryland Department of Health

March 16, 2023

Outline

- ❖ Naloxone and Opioids
- Opioids in the Workplace
- ❖ Naloxone in the Workplace Myths, Misconceptions, and Realities



Disclaimers

Dr. Mitchell has no conflicts to declare.



Opioids in the Workplace

- What are some of the known risk factors:
 - > Certain industries and occupations are known to have increased risk
 - ☐ Construction
 - ☐ Bar/restaurant workers
 - ☐ Transportation
 - ☐ Healthcare
- Obstacles to more effective management
 - "Zero tolerance" policies and stigma
 - > Injury prevention
 - ➤ Medical provider education/monitoring (Prescription Drug Monitoring)
 - Lack of good data



Naloxone and Opioids

❖ What is Naloxone?

- > Short-acting opioid antagonist chemically similar to opioids with large side groups
- > Blocks opioid receptors, reversing uptake of opioids
- > Fast acting -- 2 hour duration of action, 4 hour elimination from the body
- ➤ Naltrexone is the longer acting version
- Administration can be subcutaneous, intramuscular, intravenous, intranasal or via endotracheal tube
- \triangleright Typical dose is 0.4 2 mg
- > Few contraindications (only hypersensitivity to Naloxone)

Indications

- > Acute overdose from opioids



Naloxone in the Workplace

- On 6/1/23 Ontario workplaces will be required to have Naloxone available if employers are aware of:
 - > A risk of a worker opioid overdose.
 - A risk that the worker overdoses while in a workplace where they perform work for the employer.
 - > The risk is posed by a worker who performs work for the employer.
- The National Safety Council has urged employers to add Naloxone to their workplace first aid kits (2019)



Obstacles and Opportunities

- Concerns
 - > Legal
 - > Administrative
 - ➤ Stigma/Perception
- Opportunities

